Share this page on LinkedIn
Share This Page on Google+
Share This Page on Twitter
tell someone about this page print this page
You are here: Contents > 2018 > Volume 27 Number 1 January 2018 > CASE REPORTS > TAVI as Therapy of Choice for Aortic Valve Disease in Osteogenesis Imperfecta

TAVI as Therapy of Choice for Aortic Valve Disease in Osteogenesis Imperfecta

Jan-Philipp Minol1,3, Tobias Zeus2, Alexander Blehm1, Verena Veulemans2

1Department of Cardiovascular Surgery, University Hospital, Düsseldorf, Germany
2Department of Cardiology, Pulmonology and Angiology, University Hospital, Düsseldorf, Germany
3Electronic correspondence: phil.minol@gmx.de
Osteogenesis imperfecta (OI) is a syndrome that is often associated with dysfunction of the aortic valve. Because of the resultant fragile vessels and impaired hemostasis, surgical therapy to treat OI is challenging. Previous reports have suggested that transcatheter aortic valve implantation (TAVI) might be a suitable treatment for this condition. To the best of the authors’ knowledge,
the present case is the first to describe a young patient who underwent successful TAVI to treat osteogenesis imperfecta. The proposal of transfemoral TAVI serving as first-line therapy for aortic valve stenosis in patients suffering from osteogenesis imperfect was confirmed.

The Journal of Heart Valve Disease 2018;27:104-106


TAVI as Therapy of Choice for Aortic Valve Disease in Osteogenesis Imperfecta

Click the above hyperlink to view the article, right click (Ctrl click on a Mac) to open in a new browser window or tab.

Purchase this Article

Please click the button below to purchase this article. Single article purchases are provided at $50.00 per article. Upon clicking the button below, single article user account subscription details are requested and, upon successful payment, a single article user account is created. Single articles are availble in your account for seven days after purchase.